Peripheral blood CD31+ cells for the treatment of ischemic vascular disease.

摘要

The past decade has witnessed an unprecedented rapidity of progression from laboratory findings to clinical trials in the field of cell therapy for ischemic disease. Trials have been completed, or are currently ongoing, in patients with acute myocardial infarction, chronic ischemic heart disease, non-ischemic cardiomyopathy, and peripheral arterial disease. Much of the original pre-clinical data that underpinned these clinical trials can be attributed to Dr. Jeffrey Isner and his group in Boston who demonstrated that peripheral blood mononuclear cells (PBMCs) were capable of assuming some features of endothelial cells after brief periods of culture (1,2).